Apollomics announces two new cohorts in global Phase 2 SPARTA study

Apollomics announced the addition of two new cohorts in its ongoing global multi-cohort Phase 2 SPARTA study, which is evaluating vebreltinib in patients with non-small cell lung cancer and other solid tumors with MET dysregulations, including exon14 skipping mutation, c-MET amplification and MET fusion. The first new cohort, labeled C-2, is evaluating the addition of vebreltinib to epidermal growth factor receptor tyrosine kinase inhibitor, such as osimertinib, for patients with EGFR-mutated NSCLC progressing on first line EGFR inhibitor therapy to address acquired resistance due to c-MET amplification. The second new cohort, labeled F, will evaluate vebreltinib monotherapy in histology-agnostic solid tumors with wild type MET gene that have high expression of c-MET and hepatocyte growth factor. “We are pleased to further expand the potential target indications in our Phase 2 SPARTA study by the addition of two new cohorts to include patients for whom there are no approved target therapy for addressing the tumor proliferation and/or treatment resistance resulting from dysregulations in the HGF/c-MET axis,” said Peony Yu, M.D., Chief Medical Officer of Apollomics.